EGFR exon 21 L858R mutations

1 drugs

Predictive biomarker for patient selection in 5 indications

Approved Drugs

Indications

Companies

EGFR exon 21 L858R mutations is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 5 indications including Adjuvant therapy after tumor resection in adult patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive non-small cell lung cancer (NSCLC), Locally advanced, unresectable (stage III) EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC that has not progressed during or following platinum-based chemoradiation therapy, First-line treatment of adult patients with metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC. Explore the targeted therapies, indications, testing methods, and companies developing EGFR exon 21 L858R mutations drugs below.

Search EGFR exon 21 L858R mutations Clinical Trials

Search recruiting trials on ClinicalTrials.gov

Drugs Targeting EGFR exon 21 L858R mutations

Drug	Company	Therapeutic Area
TAGRISSO	AstraZeneca	Oncology

EGFR exon 21 L858R mutations Indications

Adjuvant therapy after tumor resection in adult patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive non-small cell lung cancer (NSCLC) Locally advanced, unresectable (stage III) EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC that has not progressed during or following platinum-based chemoradiation therapy First-line treatment of adult patients with metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC First-line treatment of adult patients with locally advanced or metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC, in combination with pemetrexed and platinum-based chemotherapy Metastatic EGFR T790M mutation-positive NSCLC in patients whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy

Companies with EGFR exon 21 L858R mutations Drugs

AstraZeneca